GLI family zinc finger 2Genealiases: CJS · HPE9 · PHS2 · THP1 · THP2
Q-omics provides the consensus-scored GLI2 profile across patient tissues and cancer cell-line models. GLI2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GLI2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GLI2 RNA expression shows 17,790 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where GLI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLI2 survival associations across molecular data types. GLI2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLI2 RNA expression–survival associations across cancer types. High GLI2 expression shows unfavorable associations in KIRP, UVM, LUAD, BLCA, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GLI2 RNA expression.
This table summarizes GLI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GLI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLI2 shows lower tumor expression in KICH, UCEC, BLCA and BRCA and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher GLI2 RNA expression in tumor versus normal tissue (log2 FC = +1.242, t-test p < 0.001).
This table shows molecular features associated with GLI2 in patient tissues and cancer cell lines. In patient samples, GLI2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
